[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848 230 7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 44, "title": "Co- Founder, CEO & Chairman", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaiyang  Tang", "age": 60, "title": "President", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiaofeng  Ye Ph.D.", "age": 46, "title": "Interim CFO and VP of Business Development & Commercialization Strategy", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Chiu  Tse M.D., Ph.D.", "age": 58, "title": "Head of Research & Development", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.46, "open": 1.52, "dayLow": 1.52, "dayHigh": 1.7178, "regularMarketPreviousClose": 1.46, "regularMarketOpen": 1.52, "regularMarketDayLow": 1.52, "regularMarketDayHigh": 1.7178, "payoutRatio": 0.0, "beta": -0.934, "forwardPE": -4.444444, "volume": 87781, "regularMarketVolume": 87781, "averageVolume": 426014, "averageVolume10days": 2503930, "averageDailyVolume10Day": 2503930, "bid": 1.6, "ask": 1.6, "bidSize": 4, "askSize": 1, "marketCap": 59040428, "fiftyTwoWeekLow": 0.879, "fiftyTwoWeekHigh": 2.75, "allTimeHigh": 19.3, "allTimeLow": 0.879, "fiftyDayAverage": 1.448, "twoHundredDayAverage": 1.656345, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 177543280, "profitMargins": 0.0, "floatShares": 66714945, "sharesOutstanding": 31236934, "sharesShort": 4639, "sharesShortPriorMonth": 4796, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0001, "heldPercentInsiders": 0.0859, "heldPercentInstitutions": 0.00052, "shortRatio": 0.17, "shortPercentOfFloat": 0.0002, "impliedSharesOutstanding": 36900268, "bookValue": 0.215, "priceToBook": 7.4418607, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -42592000, "trailingEps": -1.14, "forwardEps": -0.36, "enterpriseToEbitda": -4.239, "52WeekChange": -0.25757575, "SandP52WeekChange": 0.18594909, "quoteType": "EQUITY", "currentPrice": 1.6, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 44145000, "totalCashPerShare": 0.399, "ebitda": -41885000, "totalDebt": 44567000, "quickRatio": 0.691, "currentRatio": 1.025, "debtToEquity": 562.644, "revenuePerShare": 0.061, "returnOnAssets": -0.29808, "returnOnEquity": -1.38983, "freeCashflow": -37974124, "operatingCashflow": -38569000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768003792, "regularMarketTime": 1767992400, "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "marketState": "CLOSED", "regularMarketChangePercent": 9.58904, "regularMarketPrice": 1.6, "exchange": "NGM", "messageBoardId": "finmb_1830112145", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1695994200000, "postMarketChangePercent": -3.7500038, "postMarketPrice": 1.54, "postMarketChange": -0.060000062, "regularMarketChange": 0.13999999, "regularMarketDayRange": "1.52 - 1.7178", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 426014, "fiftyTwoWeekLowChange": 0.721, "fiftyTwoWeekLowChangePercent": 0.8202503, "fiftyTwoWeekRange": "0.879 - 2.75", "fiftyTwoWeekHighChange": -1.15, "fiftyTwoWeekHighChangePercent": -0.4181818, "fiftyTwoWeekChangePercent": -25.757576, "earningsTimestampStart": 1754650740, "earningsTimestampEnd": 1755864000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.14, "epsForward": -0.36, "epsCurrentYear": -0.36, "priceEpsCurrentYear": -4.444444, "fiftyDayAverageChange": 0.15200007, "fiftyDayAverageChangePercent": 0.10497243, "twoHundredDayAverageChange": -0.056344986, "twoHundredDayAverageChangePercent": -0.034017663, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-09-29", "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "displayName": "Adlai Nortye", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]